€
2. 38
+0.06
+2.8017%
€
- Market Cap
- P/E Ratio
- Div Yield
1,648 Volume
0 Eps
€ 2.32
Previous Close Want to track 63E and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
63E trading today higher at €2.38, an increase of 2.8017% from yesterday's close, completing a monthly decrease of -4.7904% or -€0.12. Over the past 12 months, 63E stock lost -47.8689%.
63E is not paying dividends to its shareholders.
The last earnings report, released on Apr 29, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on XBRU (EUR).
63E Chart
Onward Medical (63E) FAQ
What is the stock price today?
The current price is €2.38.
On which exchange is it traded?
Onward Medical is listed on XSTU.
What is its stock symbol?
The ticker symbol is 63E.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Onward Medical ever had a stock split?
No, there has never been a stock split.
Onward Medical Profile
| Biotechnology Industry | Healthcare Sector | Mr. David L. Marver CEO | XSTU Exchange | NL0015000HT4 ISIN |
| BE Country | 137 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Onward Medical N.V. is a pioneering medical technology enterprise, established in 2014, with a core focus on innovating therapeutic solutions for spinal cord injuries. Operating out of its headquarters in Eindhoven, Netherlands, the company extends its transformative solutions both domestically and on an international scale. As a testament to its commitment to spearheading advancements in the field, Onward Medical N.V. dedicates its research and development efforts to creating platforms that promise enhanced quality of life for individuals suffering from spinal cord injuries.
Products and Services
- ARC-EX - An external, non-invasive platform aimed at mitigating the impacts of spinal cord injuries. This state-of-the-art device includes:
- A wearable stimulator that facilitates movement and potentially improves neurological function.
- A wireless programmer designed for the customization and control of stimulation patterns, tailoring treatment to individual needs.
- ARC-IM - An implantable platform designed for those seeking a more permanent solution in their journey towards recovery. Components include:
- An implantable pulse generator that delivers electrical stimulation directly to the spinal cord, aiming to restore function and mobility.
- A lead that is precisely placed near the spinal cord to ensure optimal delivery of therapeutic stimulation.
- Up-LIFT Trial - This clinical trial represents Onward Medical N.V.'s commitment to validating the safety and effectiveness of non-invasive electrical spinal cord stimulation. Specifically, it focuses on:
- Evaluating the potential of electrical stimulation to treat upper extremity functional deficits, particularly for individuals with chronic tetraplegia, promising a significant step forward in treatment possibilities.
Contact Information
Address: Schimmelt 2, Eindhoven, Netherlands, NL-5611
Phone: +44 20 7355 9810
Website: https://www.onwd.com
